Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

Neuro-Oncology

This study will be conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 3 study. Approximately 300 subjects with newly diagnosed glioblastoma who meet all eligibility criteria will be enrolled.
Neuro-Oncology
III
Merrell, Ryan
NCT03776071
VICCNEU2124

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: